Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 26.06.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers |
| 17.05.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 16.05.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers |
| 27.10.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 24.10.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ed herein. 2 Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain O |
| 16.10.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers |
| 19.09.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ement — Registration Rights Agreement” and “Item 5.02 Departure of Directors or Certain Officers; Election of Directors; |
Stammdaten
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is based in San Diego, California.
Unternehmen & Branche
| Name | Calidi Biotherapeutics, Inc. |
|---|---|
| Ticker | CLDI |
| CIK | 0001855485 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 1,5 Mio. USD |
| Beta | 1,42 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -19,906,000 | -5.95 | 8,857,000 | 3,759,000 | |
| 2025-09-30 | 10-Q | -5,149,000 | -2.21 | 14,029,000 | 6,918,000 | |
| 2025-06-30 | 10-Q | -5,715,000 | -1.99 | 9,351,000 | 1,764,000 | |
| 2025-03-31 | 10-Q | -5,062,000 | -0.18 | 15,064,000 | 6,941,000 | |
| 2024-12-31 | 10-K | -22,143,000 | -35.70 | 14,182,000 | 1,534,000 | |
| 2024-09-30 | 10-Q | -5,054,000 | -7.75 | 6,657,000 | ||
| 2024-06-30 | 10-Q | -5,767,000 | -16.75 | 6,431,000 | -11,752,000 | |
| 2024-03-31 | 10-Q | -7,225,000 | -2.03 | 7,405,000 | -14,573,000 | |
| 2023-12-31 | 10-K | -29,216,000 | -17.33 | 10,019,000 | -8,235,000 | |
| 2023-09-30 | 10-Q | -2,024,000 | -1.41 | 18,587,000 | -1,094,000 | |
| 2023-06-30 | 10-Q | -12,501,000 | -14.24 | 44,009,727 | -63,709,000 | |
| 2023-03-31 | 10-Q | -6,462,000 | -0.75 | 43,175,807 | -55,098,000 | |
| 2022-12-31 | 10-K | 45,000 | -25,427,000 | 2.99 | 2,597,000 | -50,440,000 |
| 2022-09-30 | 10-Q | 45,000 | -5,355,000 | -0.63 | 42,158,839 | -43,926,000 |
| 2022-06-30 | 10-Q | -4,576,000 | 231,020,255 | -39,643,000 | ||
| 2022-03-31 | 10-Q | -7,740,000 | 231,235,050 | -37,620,000 | ||
| 2021-12-31 | 10-K | 3,386,750 | 231,769,289 | -31,612,000 | ||
| 2021-09-30 | 10-Q | -823,289 | 232,005,361 | -18,975,372 | ||
| 2021-06-30 | 10-Q | -73,303 | -58,303 | |||
| 2021-04-30 | 10-Q | -10,000 | 15,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-08-21 | Poma Eric E | Director, Officer, Chief Executive Officer | Open Market Purchase | 25,000 | 2.00 | 50,000.00 | +100,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.